ClinicalTrials.gg

Genmab clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 77 studies whose lead sponsor is Genmab or one of 2 companies grouped under it. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Genmab with Eli Lilly and Merck KGaA, Darmstadt, Germany →

Pipeline: 9 programs

Each counted once: 9 with a study Genmab leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 4 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Genmab’s own registered studies; Genmab’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Genmab’s studies test, most open studies first — 19 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 9 more

Coming up

9 of Genmab’s studies under way reach primary completion within a year, 3 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. 1J
  9. 1J
  10. 1A
  11. 3S
  12. 1O
  13. 1N

All 9

Show 4 more

Add all 9 to your calendar (.ics) → With an account.

All 77 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1519%Recruiting 14 · Not yet recruiting 1
  • Under way, not recruiting2026%
  • Completed1216%
  • Stopped early2836%Terminated 25 · Withdrawn 3
  • Status unknown or other23%

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 1326

By the year each study started; 6 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genmab.

  • Genmab
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    72 studies
  • Merus N.V.
    Acquired — became part of Genmab, Dec 12, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Merus B.V.
    Acquired — became part of Genmab, Dec 12, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Focus areas

Conditions Genmab leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 77. Browse all 77 →